Cancer Genetics’ Proprietary Genomic Diagnostic Tests Added to National Institutes of Health’s Genetic Testing Registry

By Jamie on August 29 2014

Online database allows clinicians and patients to search for genetic and genomic tests by disease state Increases access to information about and awareness of Cancer Genetics’ proprietary diagnostic tests RUTHERFORD, N.J., Aug. 27, 2014 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), an emerging leader in DNA-based cancer diagnostics, announced today that the National […]

Continue Reading

Cancer Genetics, Inc. and Leading Pathologist From Keck Medicine of USC Collaborate to Evaluate and Optimize Genomic Panel for Lymphoma

By Jamie on August 29 2014

Collaboration will identify and evaluate new genomic markers for most common form of non-Hodgkin’s lymphoma Results of study will be optimized by CGI to validate and enhance their proprietary genomic panel for DLBCL RUTHERFORD, N.J., Aug. 25, 2014 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), an emerging leader in DNA-based cancer diagnostics, and […]

Continue Reading

Cancer Genetics, Inc. Releases the Only Comprehensive Genomic Test to Diagnose & Stratify the Most Common Form of Leukemia (CLL)

By Italia on August 4 2014

CGI’s Proprietary Genomic Panel for Diagnosis and Risk Stratification of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Is Now Licensed to Report out Risk Stratification of Patients into Three Distinct Groups CGI’s proprietary genomic test has been CLIA and NYS licensed to stratify CLL and SLL patient into three distinct outcome groups: favorable, […]

Continue Reading